SOPHiA GENETICS Enters into Collaborate with AstraZeneca to Expand Global Access to Liquid Biopsy Testing
Overview
SOPHiA GENETICS has announced a major step forward in expanding its liquid biopsy test, MSK-ACCESS®, powered by SOPHiA DDM™.
Liquid biopsy testing offers a less invasive alternative to traditional tissue biopsies, which are sometimes unsuitable due to low-quality samples or invasive procedures. It works by isolating cell-free DNA (cfDNA) from blood plasma, enabling the detection of circulating tumour DNA (ctDNA) through a simple blood test. This method is easier on patients and allows for quicker results, supporting faster clinical decision-making.
About MSK-ACCESS®
- MSK-ACCESS® powered with SOPHiA DDM™ was originally developed by Memorial Sloan Kettering Cancer Center (MSK), a leading cancer research institution.
- This test is now decentralised, using the advanced analytical capabilities and cloud-based platform of SOPHiA DDM™.
- Combining this technology with MSK’s expertise in cancer genomics provides a cutting-edge liquid biopsy solution.
This expansion follows a partnership agreement with AstraZeneca, with plans to roll out the test to 20 global locations over the next 12 months.
About the Collaboration
- The collaboration between SOPHiA GENETICS and AstraZeneca aims to make liquid biopsy tests more widely available and highlight their advantages over traditional tissue testing in certain cases.
- A real-world evidence study will further examine the operational benefits, including faster results and high-quality data from a variety of lab settings.
- SOPHiA’s partnership with AstraZeneca could significantly boost access to liquid biopsy testing, particularly in underserved regions, potentially transforming cancer diagnostics, treatment, and monitoring globally.
Leading Healthcare Adopting the Test
- Since launching MSK-ACCESS® powered with SOPHiA DDM™ in April 2024, 14 leading healthcare institutions worldwide have adopted the test.
- These include renowned cancer centres and labs in the US, Canada, Brazil, Germany, the UK, Norway, France, Nigeria, Taiwan, and India.
About AstraZeneca’s Involvement for Test Adoption
- AstraZeneca’s involvement is expected to further accelerate the adoption of this liquid biopsy test globally.
- As more hospitals and labs adopt the technology, SOPHiA GENETICS and AstraZeneca, in collaboration with leading cancer institutes, will gather valuable real-world data that could significantly advance cancer research and treatment options.
AstraZeneca’s emphasised its commitment to bringing liquid biopsy expertise to labs around the world, ensuring better access to testing and data-driven treatment options for cancer patients globally.
About the Initiative
This initiative, first announced in October 2023, is a collaborative effort between SOPHiA GENETICS, AstraZeneca, and MSK, aimed at reducing health inequalities and pushing forward cancer research globally.
